Giuseppe Vita

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4887417/publications.pdf

Version: 2024-02-01

162 papers	8,685 citations	71102 41 h-index	49909 87 g-index
167 all docs	167 docs citations	167 times ranked	10034 citing authors

#	Article	IF	Citations
1	Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates. Journal of Endocrinological Investigation, 2022, 45, 517-525.	3.3	5
2	Diagnosis of cardiac amyloid transthyretin (ATTR) amyloidosis by early (soft tissue) phase [99mTc]Tc-DPD whole body scan: comparison with late (bone) phase imaging. European Radiology, 2022, , 1.	4.5	1
3	Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy. JAMA - Journal of the American Medical Association, 2022, 327, 1456.	7.4	43
4	Prevalence and diagnostic value of extra-left ventricle echocardiographic findings in transthyretin-related cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 197-204.	3.0	5
5	Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurology, The, 2021, 20, 49-59.	10.2	93
6	Which are the factors influencing NIV adaptation and tolerance in ALS patients?. Neurological Sciences, 2021, 42, 1023-1029.	1.9	13
7	A Phase 1/2 Study of Flavocoxid, an Oral NF-ÎºB Inhibitor, in Duchenne Muscular Dystrophy. Brain Sciences, 2021, 11, 115.	2.3	9
8	Early impairment of right ventricular morphology and function in transthyretin-related cardiac amyloidosis. Journal of Cardiovascular Echography, 2021, 31, 17.	0.4	5
9	Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy. Brain Sciences, 2021, 11, 515.	2.3	8
10	Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy. Scientific Reports, 2021, 11, 9216.	3.3	3
11	Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy. Orphanet Journal of Rare Diseases, 2021, 16, 163.	2.7	8
12	Use of Drugs for ATTRv Amyloidosis in the Real World: How Therapy Is Changing Survival in a Non-Endemic Area. Brain Sciences, 2021, 11, 545.	2.3	17
13	Very Early Onset of ATTRE89Q Amyloidosis in a Homozygous Patient. The Open Neurology Journal, 2021, 15, 21-24.	0.4	0
14	Have Duchenne Muscular Dystrophy Patients an Increased Cancer Risk?. Journal of Neuromuscular Diseases, 2021, 8, 1063-1067.	2.6	3
15	Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS. Cardiology and Therapy, 2021, 10, 481-490.	2.6	8
16	Chronic migraine in the first COVID-19 lockdown: the impact of sleep, remote working, and other life/psychological changes. Neurological Sciences, 2021, 42, 4403-4418.	1.9	15
17	Acute ischemic stroke due to endocarditis from Brucella infection. Neurological Sciences, 2020, 41, 953-954.	1.9	1
18	Charcot-Marie-Tooth disease: experience from a large Italian tertiary neuromuscular center. Neurological Sciences, 2020, 41, 1239-1243.	1.9	16

#	Article	IF	Citations
19	Practical approach to respiratory emergencies in neurological diseases. Neurological Sciences, 2020, 41, 497-508.	1.9	33
20	MuSK-Associated Myasthenia Gravis: Clinical Features and Management. Frontiers in Neurology, 2020, 11, 660.	2.4	41
21	ATTRv amyloidosis Italian Registry: clinical and epidemiological data. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 259-265.	3.0	51
22	Is it the right time for an infant screening for Duchenne muscular dystrophy?. Neurological Sciences, 2020, 41, 1677-1683.	1.9	9
23	hATTR Pathology: Nerve Biopsy Results from Italian Referral Centers. Brain Sciences, 2020, 10, 780.	2.3	24
24	Advances in Treatment of ATTRv Amyloidosis: State of the Art and Future Prospects. Brain Sciences, 2020, 10, 952.	2.3	9
25	Description of a large cohort of Caucasian patients with <scp>V122I ATTRv</scp> amyloidosis: Neurological and cardiological features. Journal of the Peripheral Nervous System, 2020, 25, 273-278.	3.1	18
26	From a misdiagnosis of anorexia nervosa to a dramatic patisiran-induced improvement in a patient with ATTRE89Q amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 279-280.	3.0	3
27	The Genetic Landscape of Dystrophin Mutations in Italy: A Nationwide Study. Frontiers in Genetics, 2020, 11, 131.	2.3	49
28	Circulating microRNAs Profile in Patients With Transthyretin Variant Amyloidosis. Frontiers in Molecular Neuroscience, 2020, 13, 102.	2.9	11
29	Psychosocial impact of sport activity in neuromuscular disorders. Neurological Sciences, 2020, 41, 2561-2567.	1.9	8
30	Effect of exercise on telomere length and telomere proteins expression in mdx mice. Molecular and Cellular Biochemistry, 2020, 470, 189-197.	3.1	9
31	The 6-min walk test as a new outcome measure in Amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 15580.	3.3	2
32	Impaired myocardial strain in early stage of Duchenne muscular dystrophy: its relation with age and motor performance. Acta Myologica, 2020, 39, 191-199.	1.5	3
33	Nusinersen in type 1 spinal muscular atrophy: Twelveâ€month realâ€world data. Annals of Neurology, 2019, 86, 443-451.	5.3	83
34	Expanding the spectrum of genes responsible for hereditary motor neuropathies. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1171-1179.	1.9	30
35	Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies. Neurological Sciences, 2019, 40, 661-669.	1.9	32
36	Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle. Neurological Sciences, 2019, 40, 671-681.	1.9	20

#	Article	IF	Citations
37	Are novel outcome measures for Charcotâ€“Marieâ€“Tooth disease sensitive to change? The 6-minute walk test and StepWatchâ„¢ Activity Monitor in a 12-month longitudinal study. Neuromuscular Disorders, 2019, 29, 310-316.	0.6	6
38	Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol. Journal of Medical Genetics, 2019, 56, 293-300.	3.2	30
39	6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR). Neuromuscular Disorders, 2019, 29, 213-220.	0.6	14
40	Unilateral hyperhidrosis as persistently isolated feature of syringomyelia and Arnold Chiari type 1. Neurological Sciences, 2018, 39, 1607-1608.	1.9	3
41	A 5-center experience with intrathecal administration of nusinersen in SMA1 in Italy letter to the editor of european journal of pediatric neurology regarding the manuscript â€œsingle-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1â€• written by pechmann and colleaguesâ€• European Journal of Paediatric Neurology, 2018, 22, 729-731.	1.6	5
42	Vacuolated PAS-Positive Lymphocytes on Blood Smear: An Easy Screening Tool and a Possible Biomarker for Monitoring Therapeutic Responses in Late Onset Pompe Disease (LOPD). Frontiers in Neurology, 2018, 9, 880.	2.4	7
43	The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage. Orphanet Journal of Rare Diseases, 2018, 13, 176.	2.7	31
44	Hippo signaling pathway is altered in Duchenne muscular dystrophy. PLoS ONE, 2018, 13, e0205514.	2.5	37
45	Agenesis of the Internal Carotid Artery Associated with Generalized Epilepsy. Journal of Clinical		

#	Article	IF	Citations
55	Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 1489-1498.	13.7	365
56	Non-invasive cardiac imaging in patients with systemic amyloidosis: a practical approach with emphasis on clinical contribution of bone-seeking radiotracers. Clinical and Translational Imaging, 2017, 5, 545-559.	2.1	3
57	Phenotypic variability of TTR Val122Ile mutation: a Caucasian patient with axonal neuropathy and normal heart. Neurological Sciences, 2017, 38, 525-526.	1.9	15
58	Increase in Synchronization of Autonomic Rhythms between Individuals When Listening to Music. Frontiers in Physiology, 2017, 8, 785.	2.8	43
59	Integrated care of muscular dystrophies in Italy. Part 1. Pharmacological treatment and rehabilitative interventions. Acta Myologica, 2017, 36, 19-24.	1.5	4
60	Integrated care of muscular dystrophies in Italy. Part 2. Psychological treatments, social and welfare support, and financial costs. Acta Myologica, 2017, 36, 41-45.	1.5	6
61	Left atrial function in cardiac amyloidosis. Journal of Cardiovascular Medicine, 2016, 17, 113-121.	1.5	21
62	Parenteral nutrition improves nutritional status, autonomic symptoms and quality of life in transthyretin amyloid polyneuropathy. Neuromuscular Disorders, 2016, 26, 374-377.	0.6	13
63	Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2016, 26, 643-649.	0.6	144
64	Myasthenia Gravis: Unusual Presentations and Diagnostic Pitfalls. Journal of Neuromuscular Diseases, 2016, 3, 413-418.	2.6	12
65	Quantitative Comparison Between Amyloid Deposition Detected by ^{99m}Tc-Diphosphonate Imaging and Myocardial Deformation Evaluated by Strain Echocardiography in Transthyretin-Related Cardiac Amyloidosis. Circulation Journal, 2016, 80, 1998-2003.	1.6	18
66	Sport activity in Charcotâ€“Marieâ€“Tooth disease: A case study of a Paralympic swimmer. Neuromuscular Disorders, 2016, 26, 614-618.	0.6	14
67	Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study. Neuromuscular Disorders, 2016, 26, 189-196.	0.6	32
68	Modulation of neuronal nitric oxide synthase and apoptosis by the isoflavone genistein in Mdx mice. BioFactors, 2015, 41, 324-329.	5.4	10
69	Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area. Journal of Neuromuscular Diseases, 2015, 2, S39-S48.	2.6	67
70	Burden, professional support, and social network in families of children and young adults with muscular dystrophies. Muscle and Nerve, 2015, 52, 13-21.	2.2	35
71	Charcotâ€“Marieâ€“Tooth 2F: phenotypic presentation of the Arg136Leu HSP27 mutation in a multigenerational family. Neurological Sciences, 2015, 36, 1003-1006.	1.9	18
72	Usefulness of Combining Electrocardiographic andÂEchocardiographic Findings and Brain Natriuretic Peptide in Early Detection of Cardiac Amyloidosis in Subjects WithÂTransthyretin Gene Mutation. American Journal of Cardiology, 2015, 116, 1122-1127.	1.6	26

#	Article	IF	Citations
73	Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy. PLoS ONE, 2015, 10, e0141240.	2.5	58
74	Socio-Economic Factors, Food Habits and Phosphorus Levels in Patients on Hemodialysis. Nephro-Urology Monthly, 2015, 7, e27114.	0.1	7
75	â€œI have got something positive out of this situationâ€: psychological benefits of caregiving in relatives of young people with muscular dystrophy. Journal of Neurology, 2014, 261, 188-195.	3.6	37
76	Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients. Neuromuscular Disorders, 2014, 24, 1003-1017.	0.6	25
77	Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice. Nature Medicine, 2014, 20, 992-1000.	30.7	113
78	The mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease. European Heart Journal Cardiovascular Imaging, 2014, 15, 1307-1315.	1.2	64
79	Psychological and practical difficulties among parents and healthy siblings of children with Duchenne vs. Becker muscular dystrophy: an Italian comparative study. Acta Myologica, 2014, 33, 136-43.	1.5	24
80	Effectiveness of skeletal scintigraphy in transthyretin-related amyloidosis. International Journal of Cardiology, 2013, 168, 4988-4989.	1.7	13
81	ANT1 is reduced in sporadic inclusion body myositis. Neurological Sciences, 2013, 34, 217-224.	1.9	9
82	Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study. European Journal of Human Genetics, 2013, 21, 630-636.	2.8	39
83	Autonomic Involvement in Subacute and Chronic Immune-Mediated Neuropathies. Autoimmune Diseases, 2013, 2013, 1-7.	0.6	6
84	Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology, 2012, 79, 159-162.	1.1	81
85	Expression of muscle-specific integrins in masseter muscle fibers during malocclusion disease. International Journal of Molecular Medicine, 2012, 30, 235-242.	4.0	44
86	Clinical features and new molecular findings in muscle phosphofructokinase deficiency (GSD type VII). Neuromuscular Disorders, 2012, 22, 325-330.	0.6	44
87	Auditory system involvement in late onset Pompe disease: A study of 20 Italian patients. Molecular Genetics and Metabolism, 2012, 107, 480-484.	1.1	26
88	Transthyretinâ€related familial amyloidotic polyneuropathy: description of a cohort of patients with Leu64 mutation and late onset. Journal of the Peripheral Nervous System, 2012, 17, 385-390.	3.1	41
89	Unusual features of central nervous system involvement in <scp>CMTX</scp> associated with a novel mutation of <scp>GJB1</scp> gene. Journal of the Peripheral Nervous System, 2012, 17, 407-411.	3.1	13
90	Muscle fat-fraction and mapping in Duchenne muscular dystrophy: evaluation of disease distribution and correlation with clinical assessments. Skeletal Radiology, 2012, 41, 955-961.	2.0	105

#	Article	IF	Citations
91	Subacute inflammatory demyelinating polyneuropathy disclosed by massive nerve root enhancement in CMT1A. Muscle and Nerve, 2012, 45, 451-452.	2.2	10
92	Telomere shortening is associated to TRF1 and PARP1 overexpression in Duchenne muscular dystrophy. Neurobiology of Aging, 2011, 32, 2190-2197.	3.1	31
93	The soy isoflavone genistein blunts nuclear factor kappa-B, MAPKs and TNF-Î± activation and ameliorates muscle function and morphology in mdx mice. Neuromuscular Disorders, 2011, 21, 579-589.	0.6	31
94	Endocardial and Epicardial Deformations in Cardiac Amyloidosis and Hypertrophic Cardiomyopathy. Circulation Journal, 2011, 75, 1200-1208.	1.6	54
95	Ascorbic acid in Charcotâ€“Marieâ€“Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurology, The, 2011, 10, 320-328.	10.2	222
96	MRI of Cardiac Involvement in Transthyretin Familial Amyloid Polyneuropathy. American Journal of Roentgenology, 2010, 195, W394-W399.	2.2	58
97	Reduced Adult Neurogenesis and Altered Emotional Behaviors in Autoimmune-Prone B-Cell Activating Factor Transgenic Mice. Biological Psychiatry, 2010, 67, 558-566.	1.3	52
98	North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2010, 20, 712-716.	0.6	171
99	miR-21 and 221 upregulation and miR-181b downregulation in human grade IIâ€“IV astrocytic tumors. Journal of Neuro-Oncology, 2009, 93, 325-332.	2.9	211
100	Psychosocial impact of presymptomatic genetic testing for transthyretin amyloidotic polyneuropathy. Neuromuscular Disorders, 2009, 19, 44-48.	0.6	20
101	Immune-mediated rippling muscle disease with myasthenia gravis: A report of seven patients with long-term follow-up in two. Neuromuscular Disorders, 2009, 19, 223-228.	0.6	36
102	Sleep disorders in children with Attention-Deficit/Hyperactivity Disorder (ADHD) recorded overnight by video-polysomnography. Sleep Medicine, 2009, 10, 1132-1138.	1.6	152
103	Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: A comparison study with methylprednisolone. Experimental Neurology, 2009, 220, 349-358.	4.1	58
104	Charcot-Marie-Tooth and pain: correlations with neurophysiological, clinical, and disability findings. Neurological Sciences, 2008, 29, 193-194.	1.9	32
105	Nuclear factorâ€ÎºB activation and differential expression of survivin and Bclâ€2 in human grade 2â€“4 astrocytomas. Cancer, 2008, 112, 2258-2266.	4.1	70
106	Correlation between clinical/neurophysiological findings and quality of life in Charcotâ€Marieâ€Tooth type 1A. Journal of the Peripheral Nervous System, 2008, 13, 64-70.	3.1	37
107	Novel SHOX Gene Mutation in a Short Boy with Becker Muscular Dystrophy: Double Trouble in Two Adjacent Genes. Hormone Research in Paediatrics, 2008, 69, 124-128.	1.8	4
108	VEGF overexpression via adenoâ€associated virus gene transfer promotes skeletal muscle regeneration and enhances muscle function in mdx mice. FASEB Journal, 2007, 21, 3737-3746.	0.5	95

#	Article	IF	Citations
109	Identification of the infant-type R631C mutation in patients with the benign muscular form of CPT2 deficiency. Neuromuscular Disorders, 2007, 17, 960-963.	0.6	9
110	Ictal and interictal EEG abnormalities in ADHD children recorded over night by video-polysomnography. Epilepsy Research, 2007, 75, 130-137.	1.6	90
111	RAGE-NF-?B pathway activation in response to oxidative stress in facioscapulohumeral muscular dystrophy. Acta Neurologica Scandinavica, 2007, 115, 115-121.	2.1	53
112	Expression of transglutaminase 2 does not differentiate focal myositis from generalized inflammatory myopathies. Acta Neurologica Scandinavica, 2007, 117, 393-398.	2.1	4
113	Evidence of cardiovascular autonomic impairment in mitochondrial disorders. Journal of Neurology, 2007, 254, 1498-1503.	3.6	17
114	Lipid Peroxidation Inhibition Blunts Nuclear Factor-Î¹B Activation, Reduces Skeletal Muscle Degeneration, and Enhances Muscle Function in mdx Mice. American Journal of Pathology, 2006, 168, 918-926.	3.8	105
115	Diffuse metabolic changes in the brain of patients with familial amyloid polyneuropathy. A proton MRSI study. Journal of the Neurological Sciences, 2006, 246, 31-35.	0.6	4
116	A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): The study protocol [EudraCT no.: 2006-000032-27]. Pharmacological Research, 2006, 54, 436-441.	7.1	47
117	Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice. Experimental Neurology, 2006, 198, 234-241.	4.1	128
118	Osteosclerotic Myeloma With Spinal Leptomeningitis and Severe Polyneuropathy. Journal of Computer Assisted Tomography, 2006, 30, 649-652.	0.9	3
119	Immunohistochemical analysis of human skeletal muscle AMP deaminase deficiency. Evidence of a correlation between the muscle HPRG content and the level of the residual AMP deaminase activity. Journal of Muscle Research and Cell Motility, 2006, 27, 83-92.	2.0	10
120	Immunolocalization and activation of nuclear factor-Î¹B in the sciatic nerves of rats with experimental autoimmune neuritis. Journal of Neuroimmunology, 2006, 174, 32-38.	2.3	14
121	Expression of Telomeric Repeat Binding Factor-1 in Astroglial Brain Tumors. Neurosurgery, 2005, 56, 802-810.	1.1	16
122	Autonomic function in elderly uremics studied by spectral analysis of heart rate. Kidney International, 2005, 67, 1521-1525.	5.2	25
123	Fatal exacerbation of peripheral neuropathy during lamivudine therapy: evidence for iatrogenic mitochondrial damage. Anaesthesia, 2005, 60, 806-810.	3.8	15
124	Specific matrix metalloproteinase expression in focal myositis: an immunopathological study. Acta Neurologica Scandinavica, 2005, 112, 173-177.	2.1	13
125	Oxidative stress in myotonic dystrophy type 1. Free Radical Research, 2005, 39, 771-776.	3.3	45
126	Expression of the tumor necrosis factor receptorâ€"associated factors 1 and 2 and regulation of the nuclear factorâ€"kB antiapoptotic activity in human gliomas. Journal of Neurosurgery, 2005, 103, 873-881.	1.6	35

#	Article	IF	Citations
127	Recurrent syncope as persistently isolated feature of transthyretin amyloidotic polyneuropathy. Neuromuscular Disorders, 2005, 15, 259-261.	0.6	15
128	Asymptomatic hyperCKemia in a case of Danon disease due to a missense mutation in Lamp-2 gene. Neuromuscular Disorders, 2005, 15, 409-411.	0.6	31
129	Comparison of different techniques for detecting 17p12 duplication in CMT1A. Neuromuscular Disorders, 2005, 15, 488-492.	0.6	10
130	Immunolocalization and Activation of Transcription Factor Nuclear Factor Î¤B in Dysimmune Neuropathies and Familial Amyloidotic Polyneuropathy. Archives of Neurology, 2004, 61, 1097-102.	4.5	19
131	Calpain 3 deficiency in Quail Eater's disease. Annals of Neurology, 2004, 55, 146-147.	5.3	5
132	Axial myopathy in myasthenia: A misleading cause of dropped head. Muscle and Nerve, 2004, 29, 329-330.	2.2	19
133	Motor function-muscle strength relationship in spinal muscular atrophy. Muscle and Nerve, 2004, 29, 548-552.	2.2	81
134	Cardiovascular autonomic control in myotonic dystrophy type 1: a correlative study with clinical and genetic data. Neuromuscular Disorders, 2004, 14, 136-141.	0.6	30
135	Role of Gabapentin in Spinal Muscular Atrophy. Journal of Child Neurology, 2003, 18, 537-541.	1.4	86
136	A family with autosomal dominant mutilating neuropathy not linked to either Charcotâ€“Marieâ€“Tooth disease type 2B (CMT2B) or hereditary sensory neuropathy type I (HSN I) loci. Neuromuscular Disorders, 2002, 12, 286-291.	0.6	9
137	Multifocal motor neuropathy and asymptomatic Hashimoto's thyroiditis: first report of an association. Neuromuscular Disorders, 2002, 12, 566-568.	0.6	37
138	Limb-girdle myasthenia: clinical, electrophysiological and morphological features in familial and autoimmune cases. Neuromuscular Disorders, 2002, 12, 964-969.	0.6	39
139	Apoptosis and apoptosis-related proteins in thyroid myopathies. Muscle and Nerve, 2002, 26, 383-388.	2.2	5
140	Cardiovascular autonomic control in Becker muscular dystrophy. Journal of the Neurological Sciences, 2001, 186, 45-49.	0.6	46
141	Endocrine Evaluation for Muscle Pain. Journal of the Royal Society of Medicine, 2001, 94, 405-407.	2.0	20
142	Autonomic dysfunction in uremia. American Journal of Kidney Diseases, 2001, 38, S118-S121.	1.9	22
143	Recurrent low back pain in familial bisalbuminemia. The Pain Clinic, 2000, 12, 329-331.	0.1	0
144	Uremic autonomic neuropathy studied by spectral analysis of heart rate. Kidney International, 1999, 56, 232-237.	5.2	104

#	Article	IF	Citations
145	Quantitation of argyrophilic nucleolar organizer regions in regenerating muscle fibers in Duchenne and Becker muscular dystrophies and polymyositis. Acta Neuropathologica, 1999, 97, 247-252.	7.7	9
146	Why do some Friedreich's ataxia patients retain tendon reflexes?. Journal of Neurology, 1999, 246, 353-357.	3.6	36
147	Dp116, talin, vinculin and vimentin immunoreactivities following nerve transection. NeuroReport, 1998, 9, 697-702.	1.2	7
148	Apoptosis in metabolic myopathies. NeuroReport, 1998, 9, 2431-2435.	1.2	26
149	Perineurium talin immunoreactivity decreases in diabetic neuropathy. Journal of the Neurological Sciences, 1997, 146, 7-11.	0.6	7
150	Extra-muscle involvement in dystrophinopathies: an electroretinography and evoked potential study. Journal of the Neurological Sciences, 1997, 146, 127-132.	0.6	27
151	Molecular basis of muscle phosphoglycerate mutase (PGAM-M) deficiency in the Italian kindred. , 1996, 19, 1134-1137.		32
152	Letters to the Editor. Muscle and Nerve, 1996, 19, 926-931.	2.2	5
153	Localization of vinculin and talin at perineurial cells of human sural nerve. NeuroReport, 1995, 6, 2077-2080.	1.2	4
154	Letter to the editor. Muscle and Nerve, 1995, 18, 251-257.	2.2	1
155	Immunocytochemistry of muscle cytoskeletal proteins in acid maltase deficiency. Muscle and Nerve, 1994, 17, 655-661.	2.2	14
156	Fetus-like dystrophin expression and other cytoskeletal protein abnormalities in centronuclear myopathies. Muscle and Nerve, 1994, 17, 1176-1184.	2.2	20
157	Expression of cytoskeleton proteins in central core disease. Journal of the Neurological Sciences, 1994, 124, 71-76.	0.6	25
158	Congenital muscular dystrophy: Correlation of muscle biopsy and clinical features. Pediatric Neurology, 1994, 10, 233-236.	2.1	9
159	Cardiovascular autonomic dysfunction in multiple sclerosis is likely related to brainstem lesions. Journal of the Neurological Sciences, 1993, 120, 82-86.	0.6	87
160	Uraemic autonomic neuropathy. Journal of the Autonomic Nervous System, 1990, 30, S179-S184.	1.9	39
161	Cardiovascular-Reflex Testing and Single-Fiber Electromyography in Botulism. Archives of Neurology, 1987, 44, 202.	4.5	65
162	Muscle uptake of99mTechnetium pyrophosphate in patients with neuromuscular disorders. Journal of the Neurological Sciences, 1982, 53, 1-7.	0.6	13